Board of Directors and Advisors
Fred Dinger CEO
Fred Dinger has over 25 years of experience with both large and small medical device companies. Prior to Aerin Medical, Fred served as President and Chief Executive Officer at ENTrigue Surgical, C2M Medical and OsteoBiologics, and has held leadership positions with A-Med Systems, where he served as Vice President and Chief Operating Officer, as well as Linvatec Corporation and Xomed Surgical Products, where Fred served as Vice President of Research and Development. Fred earned a Bachelor of Science in Mechanical Engineering from Cornell University and a Master of Science in Engineering Management from University of South Florida.
Scott Wolf, MD – Founder and Chief Medical Officer
Dr. Scott Wolf is a prolific medical device entrepreneur across a broad range of therapeutic areas. Scott founded Aerin Medical to create a non-surgical therapy to meet the enormous need of patients with nasal obstruction. Prior to founding Aerin Medical, Scott founded Zeltiq Aesthetics, the maker of CoolSculpting, the leading non-invasive method of fat reduction for bodysculpting. Scott’s other startups include Endogastric Solutions and Cardiac Dimensions. Scott was previously a partner at Prospect Venture Partners and a vice-president at Frazier Healthcare Ventures, both leading life science venture capital firms. Scott received his M.D. from George Washington University and his B.A. from the University of Pennsylvania.
Nael Kassar – Board Member
Nael Kassar is the principal of the KCK Group.
Greg Garfield – Board Member
Greg Garfield currently serves as Head of Medical Technology Investments for the KCK Group. Previously, Greg was the General Manager of Laryngology and Emerging Therapies for J&J’s Acclarent subsidiary, which J&J purchased for $785M. Prior to this role, Greg served as Acclarent’s Chief Operating Officer focusing on developing and commercializing products for use by ENT physicians to improve and enhance patients’ lives. Greg has many years of experience in the medical technology industry in a variety of roles.
Peter Savas – Board Member
Peter Savas has 30 years of experience in executive leadership positions with life sciences products and services companies. He is currently CEO of Alseres Pharmaceuticals, Inc., a Boston-based radiopharmaceutical company currently completing Phase 3 registration trials for a high performance neuroimaging agent used to definitively diagnose Parkinsonian Syndromes.
Peter is a Strategic Partner with SV Life Sciences Funds, an Associate Partner with Targeted Technology Funds and the Managing Partner of Tug Hill Partners, LLC where he focuses on strategy development, capital formation, executive leadership and corporate partnering.
Previously, he has served as CEO of Aderis Pharmaceuticals and has held executive leadership positions with Bristol Meyers, Waters, Millipore, Genex and Zymark. He has also served in governance and advisory roles with pSivida, StemBioSys and Sequana Medical. Peter holds a BA in Chemistry from Syracuse University and is credentialed as an Advanced Professional Director by the American College of Corporate Directors.
Greg Young – Board Member
Greg Young has over 35 years of experience investing in early stage companies as Founder and President of Teton Capital Management, which focuses on investments in technology including medical devices. He serves on several boards and advises several medical device startups in the areas of Urology, Orthopedics, Gynecology, and Otolaryngology. Greg previously served as Partner and General Manager of Melchor Venture Management (Portola Venture Fund), which focused on high‐technology early‐stage companies including investments in Software Publishing Corporation, 3COM Corporation, and The Learning Company. He is currently Chairman of the Board and previously served as CEO of S.R. Smith, LLC. Greg has a BS in Economics from University of California, Berkeley and a Masters of Business Administration from Stanford University.
Kern Bhugra – Board Member
Kern Bhugra has over 20 years of executive management experience in both start-ups and large corporations. Currently, Kern is the President of JunoPacific Corporation, a medical device design, development, and manufacturing firm with plants in California and Minnesota. He also serves on the Board of Directors for Leonis Medical and Aerin Medical as well as a non-profit educational institution in Northern California. He also serves on the medical device screening committee of a Silicon Valley angel investment group. Previously, Kern cofounded Tibion Bionic Technologies, a leader in neurological rehabilitation where he served as Chairman and CEO leading the company from concept through market entry, sales and acquisition. He has founded two additional companies in the medical device space, and has assisted in raising venture capital for several others. Kern began his career at IBM with responsibilities ranging from developing medical imaging systems to senior management in global technology operations in the US, Europe, and Asia. He received a BSEE with honors from the University of Michigan and a MSEE with emphasis in bioengineering from Stanford University.
Mark Deem – Board Observer
Mark Deem is a seasoned entrepreneur who currently spearheads the research and invention process on new clinical opportunities at The Foundry, a Menlo Park based medical device company incubator Mark joined at its inception in 1998. In this capacity, Mark leads the early stage effort in The Foundry’s new companies until the company’s CEO and Senior Staff is hired. Mark is a founder of Ardian Medical, which was acquired by Medtronic for over $1B. He has spent over twenty years in the design, testing and manufacture of medical devices and is a co-inventor on over 150 issued and pending U.S. patents. Mark earned his B.S. degree in biomedical engineering from Boston University.
Thomas Fogarty, MD – Advisor
Dr. Thomas J. Fogarty is an internationally recognized cardiovascular surgeon, inventor, entrepreneur, and vintner. He has been involved with a wide spectrum of innovations in business and technology. Dr. Fogarty has served as founder/co-founder, and Chairman/Board Member of over 33 various business and research companies, based on medical devices designed and developed by Fogarty Engineering, Inc. During the past 40 years, he has acquired 135 surgical patents, including the “industry standard” Fogarty balloon catheter and the widely used Aneurx Stent Graft that replaces open surgery aortic aneurysm. Dr. Fogarty is the recipient of countless awards and honors; most significantly, he is the recipient of the Jacobson Innovation Award of the American College of Surgeons, the 2000 Lemelson-MIT prize for Invention and Innovation and was inducted into the Inventors Hall of Fame and the National Academy of Engineering.